Sol-Gel Technologies Shares Outstanding 2016-2024 | SLGL

Sol-Gel Technologies shares outstanding from 2016 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Sol-Gel Technologies Annual Shares Outstanding
(Millions of Shares)
2023 27
2022 23
2021 23
2020 23
2019 20
2018 18
2017 6
2016 6
2015 6
Sol-Gel Technologies Quarterly Shares Outstanding
(Millions of Shares)
2024-06-30 28
2024-03-31 28
2023-12-31 27
2023-09-30 28
2023-06-30 28
2023-03-31 25
2022-12-31 23
2022-09-30 23
2022-06-30 23
2022-03-31 23
2021-12-31 23
2021-09-30 24
2021-06-30 23
2021-03-31 23
2020-12-31 23
2020-09-30 23
2020-06-30 23
2020-03-31 21
2019-12-31 20
2019-09-30 20
2019-06-30 19
2019-03-31 19
2018-12-31 18
2018-09-30 19
2018-06-30 19
2018-03-31 15
2017-12-31
2017-09-30
2017-06-30 6
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.015B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00